Shizuoka Cancer Center, Division of Thoracic Oncology, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
Lung Cancer. 2012 Jun;76(3):439-44. doi: 10.1016/j.lungcan.2011.12.012. Epub 2012 Jan 31.
To investigate whether decrease in the serum levels of pro-gastrin releasing peptide (ProGRP) and neuron-specific enolase (NSE) were correlated with the radiological response in patients with small-cell lung cancer (SCLC).
Of the 196 patients, we retrospectively reviewed 118 patients elevated baseline levels of ProGRP and NSE prior to the initial therapy (IT) who survived for more than 1 month. The radiological response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Decrease in the serum ProGRP was strongly correlated with the decrease of the sum of the tumor diameters (SOD) before the third course (ρ=0.50) and after the fourth course (ρ=0.42) of IT. Decrease in the serum NSE was weakly correlated with the decrease of the SOD after the fourth course (ρ=0.27), but not before the third courses (ρ=0.22). In the receiver operating characteristic (ROC) curves predicting 1-year survivors, the area under the curve (AUC) for percent changes in serum ProGRP before the third course were significantly larger than those for NSE (0.714 vs. 0.527, p=0.004).
Percent changes in serum ProGRP showed better correlation to SOD and prognostic impact than that of NSE.
本研究旨在探讨小细胞肺癌（SCLC）患者治疗前血清胃泌素释放肽前体（ProGRP）和神经元特异性烯醇化酶（NSE）水平的降低是否与影像学反应相关。
我们回顾性分析了 196 例患者，其中 118 例在初始治疗（IT）前 ProGRP 和 NSE 基线水平升高且存活时间超过 1 个月。采用实体瘤反应评估标准（RECIST 1.1）评估影像学反应。
血清 ProGRP 的降低与第三次治疗前（ρ=0.50）和第四次治疗后（ρ=0.42）的肿瘤直径总和（SOD）的降低呈强相关。血清 NSE 的降低与第四次治疗后的 SOD 降低呈弱相关（ρ=0.27），但与第三次治疗前的 SOD 降低无关（ρ=0.22）。在预测 1 年生存率的受试者工作特征（ROC）曲线中，第三次治疗前血清 ProGRP 百分比变化的曲线下面积（AUC）显著大于 NSE（0.714 比 0.527，p=0.004）。
血清 ProGRP 的百分比变化与 SOD 及预后影响的相关性优于 NSE。
